Blood flow to the optic nerve is reduced or cut off entirely
In a country where millions have embraced a new class of weight-loss drugs as a kind of metabolic salvation, the law is now asking a harder question: at what cost to the body's most irreplaceable senses? A federal panel has consolidated dozens of lawsuits against Novo Nordisk and Eli Lilly in Philadelphia, where a single judge will weigh whether GLP-1 medications like Ozempic and Wegovy may be quietly stealing the sight of some who take them. The outcome will not only determine legal liability, but may redefine the conversation between doctors and patients about a drug class that has reshaped American medicine.
- Patients who took popular weight-loss drugs are reporting partial or total vision loss, a consequence no one seeking a slimmer waistline anticipated.
- More than 70 lawsuits have accumulated across federal and state courts, alleging these medications starve the optic nerve of blood flow in a condition called ischemic optic neuropathy.
- A federal panel has now pulled these scattered cases into a single Philadelphia courtroom, creating a unified legal front that raises the stakes considerably for both pharmaceutical giants.
- Novo Nordisk and Eli Lilly are pushing back, insisting known risks are disclosed and that the vision problems may have nothing to do with their drugs.
- With over a quarter of American diabetic adults on GLP-1 medications — and millions more using them for weight loss — the courtroom's eventual verdict could ripple through prescribing rooms nationwide.
Um painel judicial federal dos Estados Unidos decidiu consolidar dezenas de processos contra a Novo Nordisk e a Eli Lilly, alegando que seus populares medicamentos para perda de peso causaram perda de visão em pacientes. Os casos serão reunidos em um único tribunal federal na Filadélfia, sob a supervisão da juíza Karen Marston.
No centro das ações estão o Ozempic e o Wegovy, da Novo Nordisk, além do Saxenda e do Trulicity, da Eli Lilly — todos pertencentes à classe dos agonistas GLP-1, originalmente desenvolvidos para tratar diabetes, mas amplamente prescritos para emagrecimento. Os processos alegam que esses medicamentos podem desencadear a neuropatia óptica isquêmica, uma condição grave causada pela redução do fluxo sanguíneo para o nervo óptico, resultando em perda parcial ou total da visão.
Atualmente, cerca de 30 ações tramitam em tribunais federais e outras 40 em instâncias estaduais. A onda de litígios ganhou força após um estudo publicado em julho de 2024 sugerir uma possível ligação entre os medicamentos e essa condição ocular. Esses casos serão tratados separadamente de outro conjunto de processos já em andamento, que tratam de efeitos colaterais gastrointestinais dos mesmos remédios.
A dimensão do problema é considerável: mais de um quarto dos adultos americanos com diabetes usa medicamentos GLP-1, e o uso para perda de peso se expandiu muito além desse grupo. Tanto a Novo Nordisk quanto a Eli Lilly negam as alegações, afirmando que os riscos conhecidos são devidamente informados aos pacientes. O desfecho dos processos dependerá da capacidade dos autores de estabelecer um nexo causal — e poderá redefinir como médicos prescrevem e discutem esses medicamentos com seus pacientes.
A federal judicial panel in the United States moved this week to consolidate dozens of lawsuits against two major pharmaceutical companies, Novo Nordisk and Eli Lilly, over allegations that their popular weight-loss medications have caused vision loss in patients. The decision, announced Monday, will bring the cases together in a single federal courtroom in Philadelphia, where they will be overseen by Judge Karen Marston.
The medications at the center of the litigation include Ozempic and Wegovy, made by Novo Nordisk, as well as Saxenda from the same company and Trulicity from Eli Lilly. All belong to a class of drugs called GLP-1 agonists, originally developed to treat diabetes but increasingly prescribed off-label for weight loss across America. The lawsuits claim these drugs may trigger a condition known as ischemic optic neuropathy—a serious eye problem that occurs when blood flow to the optic nerve is reduced or cut off entirely. Patients in the cases report experiencing partial or complete vision loss after taking the medications.
Currently, approximately 30 lawsuits have been filed in federal courts, with another 40 or more pending in state courts. The wave of legal action began after a study published in July 2024 raised the possibility of a connection between the drugs and this vision-threatening condition. The consolidation decision means these vision-related cases will be handled separately from another set of lawsuits already underway that focus on gastrointestinal side effects from the same medications—though both groups of cases will remain under Judge Marston's authority.
The scale of potential exposure is significant. More than a quarter of American adults with diabetes currently use GLP-1 medications, and the drugs have become extraordinarily popular among people seeking weight loss, regardless of diabetes status. This widespread use means the number of people potentially affected could be substantial, even if the actual risk proves to be rare.
Both Novo Nordisk and Eli Lilly have pushed back against the allegations, maintaining that any known risks associated with their products are properly disclosed to patients. When contacted about the consolidation decision, neither company offered public comment. The manufacturers' position rests on the argument that they have fulfilled their obligation to inform doctors and patients about the medication's safety profile, and that the vision problems may stem from other causes unrelated to the drugs themselves.
What happens next will likely hinge on whether plaintiffs can establish a causal link between the medications and vision loss, or whether the companies can demonstrate that the condition occurred independently. The consolidated proceeding in Philadelphia will allow the courts to manage the cases more efficiently and may eventually lead to a clearer picture of whether these drugs pose a genuine risk to eyesight. For the millions of Americans currently taking GLP-1 medications, the outcome could reshape how doctors prescribe these drugs and what conversations they have with patients about potential side effects.
Citações Notáveis
The manufacturers maintain that any known risks associated with their products are properly disclosed to patients— Novo Nordisk and Eli Lilly position
A Conversa do Hearth Outra perspectiva sobre a história
Why did the courts decide to consolidate these cases now, rather than let them proceed separately?
Consolidation makes practical sense when you have dozens of similar claims against the same defendants. It prevents conflicting rulings, reduces duplicative discovery, and moves things faster. But it also signals that the courts see enough commonality in the allegations to treat them as one problem rather than scattered incidents.
The companies say they disclosed the risks. Is that a defense that typically holds up in pharmaceutical litigation?
It depends on what they disclosed and when. If they knew about a risk and didn't tell doctors or patients, that's negligence. If they disclosed it properly, they've met a legal obligation. But the real question here is whether they knew—or should have known—about this vision risk before patients started losing their sight.
The study came out in July 2024. How long after that did lawsuits start appearing?
The source doesn't specify the exact timeline, but lawsuits began "after" the study was published. That suggests the research gave people a framework to understand what might have happened to them, and lawyers a reason to believe they had a case.
What's the difference between the vision cases and the gastrointestinal cases being handled separately?
They're different injuries from the same drugs. The GI cases deal with stomach and digestive problems. These are about blindness. Keeping them separate lets the court focus on the specific mechanism of harm in each group—how the drug causes that particular injury.
If the vision risk is real, what does that mean for the millions of people taking these drugs right now?
That's the tension. These drugs work well for weight loss and diabetes control. But if there's even a small chance they can cause permanent vision loss, patients deserve to know that before they start taking them. The litigation will help determine whether that risk is real and how common it is.